Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series

Low-grade serous carcinoma represents a minority of serous carcinoma. Although they have better prognosis than high-grade serous carcinoma, they respond poorly to chemotherapy. Thus, it appears necessary to find other treatments such as targeted therapies. Since <i>RAS</i> or <i>RA...

Full description

Bibliographic Details
Main Authors: Julie Niogret, Valentin Derangère, Corentin Richard, Lisa Nuttin, François Ghiringhelli, Laure Favier, Leila Bengrine Lefevre, Anthony Bergeron, Laurent Arnould, Romain Boidot
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:International Journal of Molecular Sciences
Subjects:
low-grade serous ovarian carcinoma
<i>RAS</i> mutation
MEK inhibitors
Online Access:https://www.mdpi.com/1422-0067/23/6/3343

Internet

https://www.mdpi.com/1422-0067/23/6/3343

Similar Items